このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected (GX-ICON)

2026年9月22日 更新者:Yi Du、First Affiliated Hospital of Guangxi Medical University

A Multicenter Prospective Diagnostic Accuracy Study of the 2022 International Criteria for Optic Neuritis and an Antibody-Stratified Adjunct in Acute or Subacute Visual Loss When Optic Neuritis Is Suspected in China

Optic neuritis is an important cause of acute or subacute visual loss. In clinical practice, optic neuritis must often be distinguished from other optic neuropathies, retinal diseases, anterior-segment or ocular media disorders, non-organic visual loss, and other mimics. The 2022 International Criteria for Optic Neuritis were developed to standardize the diagnosis of optic neuritis, but their performance in Chinese clinical settings, where aquaporin-4 immunoglobulin G positive and myelin oligodendrocyte glycoprotein immunoglobulin G positive optic neuritis are relatively common, remains uncertain.

This multicenter prospective observational study is enrolling patients with acute or subacute visual loss or visual dysfunction in whom optic neuritis is included in the differential diagnosis. The study is designed to evaluate the diagnostic performance of the 2022 International Criteria for Optic Neuritis alone and with an antibody-stratified adjunct. The index classifications will be compared with an expert-adjudicated reference-standard diagnosis. No experimental treatment is assigned by the study. All diagnostic tests and treatments are determined by the treating clinicians according to routine clinical care. Study data are collected using a structured protocol-defined case report form.

調査の概要

状態

募集

条件

詳細な説明

This multicenter prospective observational study evaluates the 2022 International Criteria for Optic Neuritis, alone and with an antibody-stratified adjunct, in patients initially suspected of having optic neuritis. Structured prospective data collection began on January 6, 2025. Each participant contributes one clinical episode. The cohort is not restricted to participants ultimately diagnosed with optic neuritis. Diagnostic testing and treatment are determined by the treating clinicians as part of routine care.

Baseline symptoms and ophthalmic findings are recorded using a structured electronic case report form. Available visual field, optical coherence tomography, magnetic resonance imaging, and laboratory findings are collected. Baseline and follow-up optical coherence tomography are encouraged when clinically feasible but are not required by study participation. Available follow-up findings can support reference-standard adjudication. Absence of follow-up optical coherence tomography alone does not exclude a participant from the primary analysis.

Both index strategies use baseline clinical data and eligible paraclinical information obtained within 3 months after symptom onset for the current episode, based on examination or sample collection dates. Later information will not revise either index classification. The 2022 criteria assign definite optic neuritis, possible optic neuritis, or not optic neuritis using prospectively recorded clinical findings, including actual color vision assessments rather than assumed abnormalities.

The antibody-stratified adjunct described in Table 2 of Liang and colleagues (2026) is applied only to participants with aquaporin-4 immunoglobulin G positivity or clear-positive myelin oligodendrocyte glycoprotein immunoglobulin G results in the index window. Under that framework, acute or subacute visual loss with at least one objective finding consistent with optic neuropathy supports definite optic neuritis; without such an objective finding, the adjunct category is possible optic neuritis. The final index classification is the higher-certainty category assigned by the 2022 criteria or the adjunct, using the hierarchy definite optic neuritis, possible optic neuritis, then not optic neuritis. Participants without either qualifying positive antibody result retain their original 2022 criteria classification. Unavailable antibody results are not treated as negative.

Participants are followed for up to 6 months after enrollment whenever feasible. Reference-standard adjudication uses baseline information and available clinical course, repeat examinations, investigations, treatment response, and alternative diagnoses within this period. The target is whether the current episode represents optic neuritis, not merely whether an antibody-associated disease is present.

For each participant, two experts independently assess the case in two stages. In Stage 1, current and historical aquaporin-4 immunoglobulin G and myelin oligodendrocyte glycoprotein immunoglobulin G results, including directly revealing diagnostic labels, are withheld. Stage 1 judgments are recorded and locked before antibody disclosure. In Stage 2, the same experts reassess the case after receiving available antibody results and relevant assay information. Both stages use otherwise identical case information and the same information cutoff, no later than 6 months after enrollment. At each stage, cases are classified as optic neuritis, non-optic neuritis, or indeterminate. A third expert resolves disagreements under the corresponding information restrictions; Stage 1 disagreements are resolved before disclosure.

At both stages, experts are masked to the index classifications. Personnel assigning or verifying index classifications are masked to the expert reference diagnoses. Masking antibody results from experts does not remove those results from either index strategy. Index classifications and reference diagnoses are recorded separately and finalized before comparative analysis. Stage 2 full-information adjudication is the primary reference standard. Stage 1 provides a supplementary reference for sensitivity analyses and assessment of diagnostic changes after antibody disclosure. Initial agreement between experts is summarized at each stage using percentage agreement and Cohen's kappa.

The primary analysis treats definite optic neuritis as index-positive and not optic neuritis as index-negative; possible optic neuritis is excluded from this conditional binary analysis and reported separately. A secondary low-threshold analysis treats definite or possible optic neuritis as positive. Indeterminate reference diagnoses are excluded from the corresponding binary accuracy calculations but retained in reported category distributions. Definite-classification yield is also compared within the same reference-positive participants, retaining possible classifications as not definite. Newly upgraded cases are described according to their reference diagnoses. First-stage indeterminacy does not exclude a participant from second-stage analyses. Detailed outcome definitions are provided in the outcome measures section.

At initial public registration, recruitment was ongoing, and database lock, formal reference-standard adjudication, final index classification, and the primary diagnostic accuracy analysis had not occurred. The antibody-masked stage is an amendment-added assessment; full-information expert adjudication remains the primary reference standard.

研究の種類

観察的

入学 (推定)

500

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Guangxi
      • Nanning、Guangxi、中国、530021
        • 募集
        • The First Affiliated Hospital of Guangxi Medical University
        • コンタクト:
      • Nanning、Guangxi、中国、530005
        • 募集
        • The Second Affiliated Hospital of Guangxi Medical University
        • コンタクト:
      • Nanning、Guangxi、中国、530001
        • 募集
        • Guangxi Minzu Hospital
        • コンタクト:
      • Nanning、Guangxi、中国、530022
        • 募集
        • Guangxi Jingliang Eye Hospital
        • コンタクト:
          • Mukun Zhao
          • 電話番号:+86 771 7980630
      • Nanning、Guangxi、中国、530199
        • 募集
        • Wuming Hospital of Guangxi Medical University
        • コンタクト:
          • Xiaoyuan Ma
          • 電話番号:+86 771 6226473
        • コンタクト:
          • Yihua Huang
      • Qinzhou、Guangxi、中国、535000
        • 募集
        • The Second People's Hospital of Qinzhou
        • コンタクト:
          • Fangfang Zhang
          • 電話番号:+86 777 3682222
      • Wuzhou、Guangxi、中国、543099
        • 募集
        • Wuzhou Gongren Hospital
        • コンタクト:
          • Jun Yang
          • 電話番号:+86 774 2036883
      • Yulin、Guangxi、中国、537099
        • 募集
        • The First People's Hospital of Yulin
        • コンタクト:
          • Na Li
          • 電話番号:+86 775 2683288
        • コンタクト:
          • Qingjuan Zhao
    • Jiangsu
      • Suzhou、Jiangsu、中国、215000
        • 募集
        • Lixiang Eye Hospital of Soochow University
        • コンタクト:
          • Yinbin Tang
          • 電話番号:+86 512 69359692

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Individuals with a new acute or subacute episode of visual loss or visual dysfunction in one or both eyes, for whom optic neuritis is included in the initial differential diagnosis at participating clinical centers. Each participant contributes only one clinical episode to the primary diagnostic accuracy cohort.

説明

Inclusion Criteria:

  1. Individuals presenting with a new acute or subacute episode of visual loss or visual dysfunction in one or both eyes, for whom optic neuritis is considered a reasonable differential diagnosis by the treating clinical team at the initial clinical assessment and before final diagnostic adjudication.
  2. Symptom onset of the current episode within 90 days before enrollment.

Exclusion Criteria:

1. The participant has previously been enrolled in this study. Each participant may be enrolled only once.

A history of optic neuritis or recurrent optic neuropathy before the current episode is not an exclusion criterion.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Suspected Optic Neuritis Differential-Diagnosis Cohort

Individuals with acute or subacute visual loss or visual dysfunction in whom optic neuritis is included in the differential diagnosis at initial clinical assessment. Participants undergo routine clinical evaluation, with study data collected using a structured case report form. The 2022 International Criteria for Optic Neuritis are evaluated alone and with the antibody-stratified adjunct. No treatment is assigned by the study.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Diagnostic Performance of the 2022 International Criteria for Optic Neuritis
時間枠:Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios, with 95 percent confidence intervals, of the 2022 International Criteria for Optic Neuritis against Stage 2 full-information expert adjudication. Definite optic neuritis is index-positive and not optic neuritis is index-negative. Possible optic neuritis and indeterminate reference diagnoses are excluded from this conditional binary analysis and reported separately.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

二次結果の測定

結果測定
メジャーの説明
時間枠
Diagnostic Yield of Definite Optic Neuritis Classification
時間枠:Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Among participants with optic neuritis according to Stage 2 full-information expert adjudication, the proportion classified as definite optic neuritis by the 2022 International Criteria for Optic Neuritis. Possible optic neuritis and not optic neuritis classifications remain in the denominator.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
Diagnostic Performance of the Antibody-Stratified Adjunct in Participants With Aquaporin-4 Immunoglobulin G Positivity or Clear-Positive Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Results
時間枠:Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Among participants with aquaporin-4 immunoglobulin G positivity or clear-positive myelin oligodendrocyte glycoprotein immunoglobulin G results in the 3-month index window, diagnostic performance of the 2022 criteria alone and with the adjunct will be compared against Stage 2 full-information expert adjudication. Sensitivity, specificity, predictive values, and likelihood ratios with 95 percent confidence intervals will use the conditional and low-threshold definitions specified for the full-cohort comparison. Results will be reported for this subgroup overall and separately by antibody type. Definite-classification yield and reference diagnoses of newly upgraded cases will also be reported. Indeterminate reference diagnoses are excluded from binary accuracy calculations and reported separately.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
Diagnostic Performance of the Low-Threshold 2022 Criteria Definition
時間枠:Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios, with 95 percent confidence intervals, when definite or possible optic neuritis is index-positive and not optic neuritis is index-negative under the 2022 criteria. Stage 2 full-information expert adjudication is the reference standard. Indeterminate reference diagnoses are excluded from binary accuracy calculations and reported separately.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
Diagnostic Performance of the 2022 International Criteria for Optic Neuritis With the Antibody-Stratified Adjunct
時間枠:Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

In the full cohort, performance of the 2022 criteria with the adjunct will be compared with the original criteria against Stage 2 full-information expert adjudication. In the conditional analysis, definite optic neuritis is positive and not optic neuritis is negative; possible optic neuritis is excluded. In the low-threshold analysis, definite or possible optic neuritis is positive and not optic neuritis is negative. Sensitivity, specificity, predictive values, likelihood ratios, and 95 percent confidence intervals will be reported. Definite-classification yield will also be compared in the same reference-positive participants, retaining possible classifications as not definite. Reference diagnoses of newly upgraded cases will be reported. Indeterminate reference diagnoses are excluded from binary accuracy calculations but reported separately.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
Proportion of Indeterminate Reference-Standard Diagnoses
時間枠:Up to 6 Months After Enrollment

Proportion of participants assessed by the Stage 2 full-information expert adjudication panel whose reference-standard diagnosis is indeterminate.

Up to 6 Months After Enrollment
Distribution of 2022 International Criteria for Optic Neuritis Classifications
時間枠:Baseline and diagnostic-window data for the current episode, within 3 months after symptom onset

Proportion of participants classified as definite optic neuritis, possible optic neuritis, or not optic neuritis by the 2022 International Criteria for Optic Neuritis.

Baseline and diagnostic-window data for the current episode, within 3 months after symptom onset
Change in Expert-Adjudicated Diagnosis After Disclosure of Aquaporin-4 Immunoglobulin G and Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Results
時間枠:Paired adjudications using baseline and follow-up information available up to 6 months after enrollment

Among participants with at least one aquaporin-4 immunoglobulin G or myelin oligodendrocyte glycoprotein immunoglobulin G result available within the reference-standard information window and completed adjudications at both stages, the proportion whose diagnosis changes after disclosure. The direction of change between optic neuritis, non-optic neuritis, and indeterminate diagnoses will be reported, overall and by antibody status. Participants with neither antibody result available, or with an adjudication missing at either stage, are excluded from this proportion and reported separately. Diagnostic change is not assumed to represent correction of an error.

Paired adjudications using baseline and follow-up information available up to 6 months after enrollment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Yi Du, MD, PhD、First Affiliated Hospital of Guangxi Medical University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年1月6日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2028年1月1日

試験登録日

最初に提出

2026年5月11日

QC基準を満たした最初の提出物

2026年5月29日

最初の投稿 (実際)

2026年6月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • GX-ICON

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified participant-level data and a data dictionary will be made available to qualified researchers upon reasonable request after publication of the main diagnostic accuracy results, subject to ethics approval, institutional approval, and execution of a data use agreement.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。